Gabather AB (FRA:5J2) OCF Margin %: 0.00% (As of Mar. 2026)


What is Gabather AB OCF Margin %?

Gabather AB FRA:5J2 OCF Margin % is 0.00% as of Mar. 2026. The stock has 2 warning signs investors should review. Among 956 Drug Manufacturers companies, Gabather AB ranks worse than 104602.41% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Gabather AB's Cash Flow from Operations for the three months ended in Mar. 2026 was €-0.03 Mil. Gabather AB's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Gabather AB's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Gabather AB's current OCF Yield % is -27.78%.

The historical rank and industry rank for Gabather AB's OCF Margin % or its related term are showing as below:


FRA:5J2's OCF Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.985
* Ranked among companies with meaningful OCF Margin % only.

Gabather AB OCF Margin % Related Terms

Gabather AB OCF Margin % Historical Data

* Premium members only.

The historical data trend for Gabather AB's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gabather AB OCF Margin % Chart

Gabather AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Gabather AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Gabather AB OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Gabather AB's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-0.664/0
= %

Gabather AB's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.031/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Gabather AB (FRA:5J2) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Gabather AB and its competitors. According to the industry distribution chart, Gabather AB ranks #999999 out of 956 companies in the Drug Manufacturers industry.
Is Gabather AB's OCF Margin % too high?
Gabather AB's current OCF Margin % is 0.00%. Based on the distribution chart, Gabather AB ranks #999999 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Gabather AB's OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gabather AB ranks #999999 out of 956 companies for OCF Margin %. This places Gabather AB in the lower half of its industry. The industry median OCF Margin % is 9.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.99, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Gabather AB and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gabather AB's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gabather AB stock overvalued right now?
Gabather AB (FRA:5J2) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Gabather AB (FRA:5J2), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gabather AB Business Description

Other Exchanges GABA:Sweden
Address Forskargatan 20J, Byggn 215 N, Sodertalje, SWE, 151 36
Gabather AB is engaged in developing novel drugs to treat several diseases originating in the central nervous system. It has four main focus areas anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as cognition-enhancing treatments, including for Alzheimer's disease.